Pac Premier
Giving Guide
You are here:  Home  >  Banking & Finance  >  Personal Finance  >  Current Article

Amgen earnings keep rising

By   /   Thursday, October 23rd, 2008  /   Comments Off on Amgen earnings keep rising

    Print       Email

Amid some of the worst market plunges in Wall Street’s history, Thousand Oaks-based Amgen continues to blaze a comeback trail.

The company cut hard and deep last year, shedding more than 1,000 jobs after a tempest of regulatory woes. But third quarter profits have surged, and the company’s shares have proved buoyant amid turbulent markets.

The company, the world’s largest biotech firm by market capitalization, posted third-quarter profits of $1.16 billion, or $1.09 a share compared to last year’s $1.08, slightly beating analyst expectations. Revenue also beat expectations, rising to $3.8 billion, or 7 percent compared to $3.6 billion last year. Analysts surveyed by Yahoo! Finance had predicted third-quarter earnings per share of $1.08 on revenue of $3.7 billion.

Between June and mid-September, Amgen’s shares surged from $45 to $65 on promising test reports on a new osteoporosis drugs and on nervous investors moving toward what are viewed as more recession-proof stocks. Although recent weeks have stung the stock, shares are still up for the year.

At a corporate leadership breakfast sponsored by California Lutheran University on Oct. 21, Scott Foraker, an executive vice president in charge of Amgen’s research and development activities, spoke to a crowd of about 150 people and provided insights to how Amgen – Ventura County’s largest private employer with 6,800 workers – built itself into a Fortune 200 company.

For one thing, Foraker said, the company knew when to take big risks, such as the wrangling over whether and how to license one of its prime money-makers, the anemia drug Aranesp, to pharmaceutical giant Johnson & Johnson.

“We rolled the dice with that arbitration,” Foraker said. “We rolled the dice and won.”

Amgen has also timed well its manufacturing investments, which are often hundreds of millions of dollars. A company that pulls the trigger too early or too late, Foraker said, risks either losing its investment or running short of its drug.

“Making biotech products is tough – many companies have gotten this wrong,” Foraker said. “It’s not like making pills.”

Foraker also said that Amgen has leavened its blockbuster drugs small-population offerings such as Nplate, a treatment for a rare immune system disease that reduces platelet counts.

“It certainly won’t be our biggest drug,” Foraker said. But, “this is the only drug on the market for low platelet counts.”

    Print       Email